Open Label Safety Study in Acute Treatment of Migraine

Completed · Phase 2/Phase 3

Conditions studied: Migraine, With or Without Aura

In brief

The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).

Key facts

Study ID
NCT03266588
Run by
Pfizer
People needed
3019
Starts
2017-08-30
Expected to finish
2019-07-15
Last updated by the study team
2023-02-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.